Search
Maze Therapeutics Inc
MAZEAdd to Watchlist
28.550USD
+0.860+3.11%
Close 07-23 16:00（ET）Quotes delayed by 15 min
1.41BMarket Cap
LossP/E TTM
More Details of Maze Therapeutics Inc Company
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Maze Therapeutics Inc Info
Ticker SymbolMAZE
Company nameMaze Therapeutics Inc
IPO dateJan 31, 2025
CEOColoma (Jason V)
Number of employees125
Security typeOrdinary Share
Fiscal year-endJan 31
Address171 Oyster Point Boulevard, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16508505070
Websitehttps://www.mazetx.com/
Ticker SymbolMAZE
IPO dateJan 31, 2025
CEOColoma (Jason V)
Company Executives of Maze Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
23.25K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
23.25K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
FAQs
Who are the top five shareholders of Maze Therapeutics Inc?
The top five shareholders of Maze Therapeutics Inc are: Dr. Jonathan E. Lim, M.D.
How many institutions hold shares of Maze Therapeutics Inc (MAZE)?
As of 2026Q1, 213 institutions hold shares of Maze Therapeutics Inc, with a combined market value of approximately 53.41M, accounting for 97.33% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 12392855.00.